MedPath
Found 13 clinical trials|View Analysis
Sort by:

Finite Treatment of Hepatitis Delta with Bulevirtide: Identification of Biomarkers Associated with Sustained Control of HDV Infection

Not Applicable
Not yet recruiting
Conditions
Compensated Liver Disease (Disorder)
Hepatitis D, Chronic
Interventions
Other: Stop Treatment with Bulevertide in patients with compensated liver disease and chronic HDV infection
First Posted Date
2024-09-19
Last Posted Date
2024-09-19
Lead Sponsor
Hannover Medical School
Target Recruit Count
20
Registration Number
NCT06603311
Locations
🇩🇪

Department of Gastroenterology, Hepatology, Infectious Diseases and Endocrinology, Hannover Medical School, Hannover, Lower Saxony, Germany

SOLSTICE: Combination Therapy for the Treatment of Chronic Hepatitis D Infection.

Phase 2
Recruiting
Conditions
Hepatitis D, Chronic
Interventions
Drug: VIR-3434
Drug: VIR-2218
Drug: NRTI
First Posted Date
2022-07-18
Last Posted Date
2024-08-09
Lead Sponsor
Vir Biotechnology, Inc.
Target Recruit Count
124
Registration Number
NCT05461170
Locations
🇬🇧

Investigative Site, Manchester, United Kingdom

Once Daily Dosing of Lonafarnib Co-administered With Ritonavir for Treatment of Chronic Hepatitis D Virus Infection

Phase 3
Active, not recruiting
Conditions
Hepatitis D, Chronic
Interventions
First Posted Date
2022-02-08
Last Posted Date
2023-05-06
Lead Sponsor
Soroka University Medical Center
Target Recruit Count
30
Registration Number
NCT05229991
Locations
🇳🇿

New Zealand Liver Transplant Unit, Auckland City Hospital, Auckland, New Zealand

🇹🇷

Department of Gastroenterology and Hepatology, Koç University Medical School, Istanbul, Turkey, Istanbul, Turkey

🇮🇱

Soroka UMC, Be'er Sheva, Israel

A Study of JNJ-73763989 + Nucleos(t)Ide Analog in Participants Co-Infected With Hepatitis B and Hepatitis D Virus

Phase 2
Active, not recruiting
Conditions
Hepatitis D, Chronic
Interventions
First Posted Date
2020-09-02
Last Posted Date
2024-12-09
Lead Sponsor
Janssen Research & Development, LLC
Target Recruit Count
52
Registration Number
NCT04535544
Locations
🇯🇵

National Hospital Organization Shikoku Cancer Center, Iizuka-shi, Japan

🇺🇸

Stanford University School of Medicine, Redwood City, California, United States

🇺🇸

Harvard Medical School Massachusetts General Hospital, Boston, Massachusetts, United States

and more 58 locations

Observatory of Efficacy and Safety of Bulevirtide in Patients With Chronic HBV/HDV Co-infection

Recruiting
Conditions
Hepatitis B, Chronic
Hepatitis D, Chronic
First Posted Date
2019-11-18
Last Posted Date
2023-08-21
Lead Sponsor
ANRS, Emerging Infectious Diseases
Target Recruit Count
400
Registration Number
NCT04166266
Locations
🇫🇷

Saint-Antoine Hospital, Paris, France

🇫🇷

CHU of Angers, Angers, France

🇫🇷

Pitié-Salpêtrière Hospital, Paris, France

and more 8 locations

Pegylated Interferon Alone or in Combination With Ezetimibe for Patients With Chronic Hepatitis D

Phase 2
Conditions
Hepatitis D, Chronic
Interventions
Drug: Pegylated interferon alfa
Drug: Ezetimibe
First Posted Date
2017-04-07
Last Posted Date
2017-04-07
Lead Sponsor
Aga Khan University
Target Recruit Count
20
Registration Number
NCT03105310

A Long Term Follow-up Study of Patients From the REP 301 Protocol

Completed
Conditions
Hepatitis D, Chronic
Hepatitis B, Chronic
First Posted Date
2016-08-23
Last Posted Date
2020-10-06
Lead Sponsor
Replicor Inc.
Target Recruit Count
11
Registration Number
NCT02876419
Locations
🇲🇩

Infectious Clinical Hospital (n.a. Toma Ciorba), Chisinau, Moldova, Republic of

A Study to Evaluate Pegylated Interferon Lambda Monotherapy in Patients With Chronic Hepatitis Delta Virus Infection

Phase 2
Completed
Conditions
Hepatitis D, Chronic
Interventions
First Posted Date
2016-05-09
Last Posted Date
2023-01-17
Lead Sponsor
Eiger BioPharmaceuticals
Target Recruit Count
33
Registration Number
NCT02765802
Locations
🇮🇱

Soroka Medical Center, Beersheba, Israel

🇳🇿

Auckland City Hospital, Grafton, Auckland, New Zealand

🇮🇱

Shaare Zedek Medical Center, Jerusalem, Israel

and more 1 locations

A Study of Pegylated Interferon (PEG-IFN) Alfa-2a (Pegasys) in Participants With Chronic Hepatitis D (CHD)

Phase 3
Completed
Conditions
Hepatitis D, Chronic
Interventions
Drug: Pegylated Interferon (PEG-IFN) alfa-2a
First Posted Date
2016-04-08
Last Posted Date
2016-08-26
Lead Sponsor
Hoffmann-La Roche
Target Recruit Count
31
Registration Number
NCT02732639

A Study of Peginterferon Alfa-2a With or Without Ribavirin in Participants With Chronic Hepatitis D (CHD)

Phase 2
Completed
Conditions
Hepatitis D, Chronic
Interventions
First Posted Date
2016-04-07
Last Posted Date
2016-07-15
Lead Sponsor
Hoffmann-La Roche
Target Recruit Count
12
Registration Number
NCT02731131
© Copyright 2025. All Rights Reserved by MedPath